Regulation of CTLA-4 and PD-L1 Expression in Relapsing-Remitting Multiple Sclerosis Patients after Treatment with Fingolimod, IFNß-1&#945;, Glatiramer Acetate, and Dimethyl Fumarate Drugs.

Derakhshani, Afshin; Asadzadeh, Zahra; Safarpour, Hossein; Leone, Patrizia; Shadbad, Mahdi Abdoli; Heydari, Ali; Baradaran, Behzad; Racanelli, Vito

Regulation of CTLA-4 and PD-L1 Expression in Relapsing-Remitting Multiple Sclerosis Patients after Treatment with Fingolimod, IFNß-1α, Glatiramer Acetate, and Dimethyl Fumarate Drugs.

Derakhshani, Afshin; Asadzadeh, Zahra; Safarpour, Hossein; Leone, Patrizia; Shadbad, Mahdi Abdoli; Heydari, Ali; Baradaran, Behzad; Racanelli, Vito.

Afiliação

Derakhshani A; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz 516615731, Iran.
Asadzadeh Z; IRCCS Istituto Tumori "Giovanni Paolo II" of Bari, 70124 Bari, Italy.
Safarpour H; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz 516615731, Iran.
Leone P; Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand 9717853577, Iran.
Shadbad MA; Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", 70124 Bari, Italy.
Heydari A; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz 516615731, Iran.
Baradaran B; Student Research Committee, Tabriz University of Medical Sciences, Tabriz 516615731, Iran.
Racanelli V; Department of Applied Mathematics, University of California, Merced, CA 95343, USA.

J Pers Med ; 11(8)2021 Jul 27.

Article em En | MEDLINE | ID: mdl-34442365